You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Antibody Drug Conjugate (ADC)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed Solid Tumor, Refractory Cancer, Solid Tumor, Adult Trial (STI-3258)

Withdrawn
  • Relapsed Solid Neoplasm
  • +2 more
  • STI-3258
  • (no location specified)
Jan 24, 2023

Light Chain (AL) Amyloidosis Trial (STI-6129)

Not yet recruiting
  • Light Chain (AL) Amyloidosis
  • STI-6129
  • (no location specified)
Jan 11, 2023

Metastatic Solid Tumors, Esophageal Cancer, NSCLC Trial in Houston, San Antonio, Toronto (M1231)

Recruiting
  • Metastatic Solid Tumors
  • +2 more
  • Houston, Texas
  • +2 more
Jul 29, 2022

Light Chain (AL) Amyloidosis Trial in New York (STI-6129)

Recruiting
  • Light Chain (AL) Amyloidosis
  • STI-6129
  • Duarte, California
  • +3 more
Jan 12, 2023

Solid Tumor Trial in United States (TR1801-ADC)

Active, not recruiting
  • Unspecified Adult Solid Tumor, Protocol Specific
  • TR1801-ADC
  • Los Angeles, California
  • +4 more
Oct 30, 2022

Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer Trial in Australia (IKS014)

Not yet recruiting
  • Breast Cancer
  • +2 more
  • Concord, New South Wales, Australia
  • +4 more
May 30, 2023

Breast Cancer Trial (Trastuzumab Deruxtecan)

Not yet recruiting
  • Breast Cancer
  • Trastuzumab Deruxtecan
  • (no location specified)
Jul 10, 2023

Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Trial in San Francisco (FOR46, Enzalutamide, Pegfilgrastim)

Recruiting
  • Metastatic Castration-resistant Prostate Cancer
  • Prostate Cancer
  • FOR46
  • +2 more
  • San Francisco, California
    University of California, San Francisco
Jun 1, 2022

Solid Tumor Trial in United Kingdom, United States (Farletuzumab ecteribulin)

Recruiting
  • Solid Tumor
  • Farletuzumab ecteribulin
  • Tucson, Arizona
  • +26 more
Jan 30, 2023

HER2 Mutation-Related Tumors, HER2 Amplification Trial (ARX788)

Not yet recruiting
  • HER2 Mutation-Related Tumors
  • HER2 Amplification
  • (no location specified)
Aug 23, 2021

Metastatic Breast Cancer Trial in Villejuif (U3-1402)

Recruiting
  • Metastatic Breast Cancer
  • Villejuif, France
    Gustave Roussy
Jul 7, 2021

Advanced/ Metastatic Solid Tumors Trial in Shanghai (FDA018-ADC)

Recruiting
  • Advanced/ Metastatic Solid Tumors
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Dec 14, 2021

Advanced Solid Tumors Trial in Canada, United States (LCB84, Anti-PD-1 mAb)

Not yet recruiting
  • Advanced Solid Tumors
  • LCB84
  • Anti-PD-1 monoclonal antibody
  • Los Angeles, California
  • +6 more
Jul 4, 2023

Breast Tumors Trial in France (DS-8201a)

Active, not recruiting
  • Breast Tumors
  • Angers, France
  • +20 more
Feb 1, 2022

Metastatic Lung Cancer Trial in Villejuif (DS-1062a)

Recruiting
  • Metastatic Lung Cancer
  • Villejuif, France
    Gustave Roussy
Jun 17, 2021

Renal Pelvis and Ureter Urothelial Carcinoma Trial in Los Angeles (procedure, drug, biological)

Not yet recruiting
  • Renal Pelvis and Ureter Urothelial Carcinoma
  • Biopsy
  • +5 more
  • Los Angeles, California
    UCLA / Jonsson Comprehensive Cancer Center
Mar 15, 2023

Metastatic Penile Squamous Cell Carcinoma, Stage III Penile Cancer AJCC v8, Stage IV Penile Cancer AJCC v8 Trial in Phoenix,

Not yet recruiting
  • Metastatic Penile Squamous Cell Carcinoma
  • +3 more
  • Enfortumab Vedotin
  • Phoenix, Arizona
  • +2 more
Oct 23, 2023

HIV Infection, HIV-associated Hodgkin Lymphoma, Stage III Adult Hodgkin Lymphoma Trial in France (brentuximab vedotin,

Active, not recruiting
  • HIV Infection
  • +3 more
  • brentuximab vedotin
  • +3 more
  • Clamart, France
  • +5 more
Aug 11, 2022

Breast Tumors, Gastric Tumor, Solid Tumors Trial in Australia, United States (ARX788)

Recruiting
  • Breast Neoplasms
  • +2 more
  • Los Angeles, California
  • +8 more
Feb 25, 2022

Relapsed/Refractory Multiple Myeloma Trial in Worldwide (Dose Escalation, MEDI2228, ADC (antibody drug conjugate), Dose

Completed
  • Relapsed/Refractory Multiple Myeloma
  • Dose Escalation, MEDI2228, ADC (antibody drug conjugate)
  • Dose Expansion, MEDI2228, ADC (antibody drug conjugate)
  • Phoenix, Arizona
  • +10 more
Mar 25, 2022

Colorectal Cancer Trial in Japan, Spain, United States (M9140)

Recruiting
  • Colorectal Cancer
  • Houston, Texas
  • +4 more
Jul 15, 2022

Reporting of Antibody-Drug Conjugate Associated Sepsis-related

Completed
  • Sepsis (SMQ)
  • +2 more
  • Antibody-Drug Conjugate
  • Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate
  • Changsha, Hunan, China
    Central South University
Jun 19, 2022

Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Seattle (drug, other,

Recruiting
  • Recurrent Hodgkin Lymphoma
  • +3 more
  • Brentuximab Vedotin
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 4, 2022

Recurrent Classic Hodgkin Lymphoma Trial in Duarte (Brentuximab Vedotin, Nivolumab)

Recruiting
  • Recurrent Classic Hodgkin Lymphoma
  • Brentuximab Vedotin
  • Nivolumab
  • Duarte, California
    City of Hope Medical Center
Feb 16, 2022

Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma Trial in Duarte (Brentuximab Vedotin, Cyclosporine, Pharmacokinetic

Active, not recruiting
  • Recurrent Hodgkin Lymphoma
  • Refractory Hodgkin Lymphoma
  • Brentuximab Vedotin
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Feb 17, 2022